TITLE

Under Review

PUB. DATE
May 2002
SOURCE
Pharmaceutical Executive;May2002, Vol. 22 Issue 5, p142
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Highlights several issues critical to the pharmaceutical industry that need to be addressed. Need to balance companies' intellectual property rights with patients' right to access lower-priced generics; Pharmacovigilance and fast-track registration; Biotechnology issues.
ACCESSION #
6673219

 

Related Articles

  • The Upcoming Biotech Battle. Santini, Laura // Investment Dealers' Digest;4/21/2003, Vol. 69 Issue 16, p9 

    Reports on the interest shown by U.S. generic drug makers in biotechnology drugs which are in danger of losing patent protection. Predicted competition between biotech companies and generic drug makers; Legal and regulatory issues; Perceived support for generic drug makers from the U.S. government.

  • Mid-year, generics and biotechs are thriving. Arnold, Matthew // Medical Marketing & Media;Oct2003, Vol. 38 Issue 10, p32 

    Reports on the increase in sales of biotechnology and generic drugs, according to June 2002 update on the global market pharmaceutical by IMS Health. Therapy sales breakdown; Generics penetration in the U.S.

  • Where Biotechs, Generics Converge. Reed, Vita // Orange County Business Journal;04/16/2001, Vol. 24 Issue 16, p60 

    Focuses the convergence of generic and biotechnology drug makers for Sicor Inc. in Irvine, California. Similarity between Sicor and Teva Pharmaceutical Industries Ltd.; Assets of biotech companies; Concerns on the intellectual property protection.

  • Patent Challenges. J. W. // Pharmaceutical Executive;Jun2007, Vol. 27 Issue 6, p24 

    The article reports that Thailand Government and other third-world nations are challenging patents on critical therapies, a tactic that is stepping up into a serious international confrontation over intellectual property protection. Thailand has been trying to override drug patents on AIDS...

  • Ethical Pharma Companies Fight Generics Head On. Scott, Alex // Chemical Week;7/5/2006, Vol. 168 Issue 23, p22 

    This article reveals that some ethical pharmaceutical companies have started to challenge the established pricing model for branded pharmaceuticals that go off patent. Merck and Pfizer have each opted to offer major price discounts on leading drugs that recently went off patent, to fight...

  • Tick-tock stop the clock Generics and extended patent protection. Wynne, Clarissa // Chemistry in Australia;Dec2010, Vol. 78 Issue 11, p7 

    The article discusses various ways in which the owner of the original compound can extend patent rights beyond the 20-year term of a patent to the original compound and prevent generic competition. The owner can apply for an extension of terms of up to five years. To extend the period of market...

  • Generic Pharmaceuticals: IP's Fiercest Litigation Arena. Andersen, Steven // Corporate Legal Times;Nov2003, Vol. 13 Issue 144, p28 

    Focuses on the complications in the generic drug application for patent rights by pharmaceutical companies in the U.S. Employment of strategy to extend the patent life of their products; Impact of the emergence of generic drugs on the pharmaceutical companies; Overview of the process of the...

  • Dynamics of India's Life Sciences Outsourcing Industry. Bhatt, Nailesh A. // Pharmaceutical Technology;Aug2007 Supplement, Vol. 31, p65 

    The tightening of intellectual property rights in India under GATT/TRIPS was a crucial inflection point for pharmaceutical outsourcing in India. With that move, pharmaceutical outsourcing to that country has evolved from limited partnering options based mainly on generic drugs and limited pure...

  • Litigation Is The Business Model For Generic Drug Maker. Andersen, Steven // Corporate Legal Times;Apr2003, Vol. 13 Issue 137, p24 

    Presents a discussion on the litigation challenges faced by Teva Pharmaceutical Industries Limited, manufacturer of generic drugs, in the U.S. Difficulty of handling international intellectual property function; Description of patents held; Competition with brand name pharmaceutical companies. ...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics